This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and
refractory advanced NSCLC.NK510 will be administered in combination with PD-1 blockade.
Patients are required to undergo a biopsy for confirmation of tumor PD-L1 expression,and
EGFR,ROS1,ALK gene must be negative. The safety and efficacy of this treatment will be
evaluated.